Our approach was to retarget our selective and potent oncolytic adenovirus Ad∆∆, to αvß6-expressing pancreatic cancers by introducing the high affinity A20FMDV integrin-ligand and ablate the CAR and CR-1 binding to erythrocytes, by generating Ad-3∆-A20T12. The gene discussed is CR1; the disease is pancreatic neoplasm.